Chronic Myeloid Leukemia Archives - Page 2 of 46

Image of chronic lymphocytic leukemia cells

Patients With CML Continue to Be Prescribed Costly Second-Gen TKIs

By

October 9, 2020

Most patients with CML are being prescribed costly second-generation TKIs, even though generic imatinib has been available since 2016.

Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.

General Oncology

How the Coronavirus Pandemic May Affect Cancer Clinical Trials

By

Agata Boxe

September 23, 2020

Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.

The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.

General Oncology

The Twitter Effect on How Oncologists Conduct and Share Research

By

Sarah Elizabeth Richards

August 12, 2020

The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.

It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.

General Oncology

How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials

By

Christina Hunter Chapman, MD, MS

August 7, 2020

It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.

Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.

General Oncology

Researchers Reveal Racial Disparities in Access to Remdesivir for Patients With Cancer and COVID-19

By

Randi Hernandez

July 24, 2020

Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.

New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.

General Oncology

Conflicts of Interest Continue to Plague Oncology Guidelines and Research

By

Agata Boxe

July 15, 2020

New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.

Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.

General Oncology

Why Cancer Centers May Need to Rethink the Hard Sell to Patients

By

Sarah Elizabeth Richards

July 14, 2020

Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.

Managing adverse effects after starting a TKI can be challenging, and health care practitioners ofte

EHA25 Virtual Congress

Study Provides Support for TKI Discontinuation in Some Patients With CML

By

Susan Moench, PhD, PA-C

June 12, 2020

This population-based study of patients with chronic phase CML evaluated the BCR/ABL1 TKI discontinuation rates for patients treated on and off a clinical trial.